Dianthus Therapeutics, Inc. (NASDAQ: DNTH) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT DIANTHUS THERAPEUTICS, INC.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
Listen to this Section


$80.10
-4.0300 ( -4.79% ) 378.8K

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Market Data


Open $80.10
Previous Close $84.13
Volume 378.8K
Market Cap $4.64B
Day Range $79.78 - $85.53
52 Week Range $16.64 - $96.50
Shares Outstanding 54.67M
Change % -4.79%
Net Change ▼ -4.0300
Insider Ownership -0.01%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2023
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -639,500.00

Date Type Amount Purchased Purchaser
2023-09-13 Sale -6500.00 MOULDER LEON O JR

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 77 Nov 05, 2025
8-k 8K-related 12 Nov 05, 2025
8-k 8K-related 83 Nov 03, 2025
8-k 8K-related 30 Oct 16, 2025
4 Insider transactions 1 Oct 03, 2025
4 Insider transactions 1 Sep 25, 2025
4 Insider transactions 1 Sep 25, 2025
8-k 8K-related 16 Sep 11, 2025
4 Insider transactions 1 Sep 11, 2025
8-k 8K-related 48 Sep 08, 2025

Latest News


× Before browsing our site, please accept our cookies policy